| 摘要 |
The present invention relates to a pharmaceutical composition for preventing or treating diabetes comprising gleevec as an active ingredient and, more specifically, a gleevec which is an inactive ligand enhances insulin sensitivity by specifically inhibiting a phosphorylation of Ser273 residues through CDK5, effectively decreases in blood sugar levels and confirms a more outstanding anti-diabetic effect due to overcoming a side effect of an existing peroxisome proliferator-activated receptor gamma (PPARγ)-targeting therapeutic agent. A pharmaceutical composition comprising gleevec as an active ingredient of the present invention can be especially useful in alleviating or treating type 2 diabetes mellitus and metabolic diseases. |
